Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6 Lymphoid 4 Gastrointestinal 4 Genitourinary 3 Other solid neoplasm 2 Thoracic 1 Plasma cell 1 Other 1 Myeloid 1 CNS 1 Breast 1

Conditions

Neurofibromatosis 1 1

Interventions

Temozolomide 610 Radiotherapy 387 Bevacizumab 253 Magnetic Resonance Spectroscopy 202 Cyclophosphamide 177 Carboplatin 159 Radiosurgery 145 Etoposide 132 Radiation 120 Irinotecan 115 Vincristine 114 Cisplatin 102 Filgrastim 100 Specimen Handling 88 Nivolumab 87 pembrolizumab 81 Lomustine 80 Topotecan 73 Surgical Procedures, Operative 73 Doxorubicin 60 Melphalan 59 Carmustine 57 sargramostim 53 Radiotherapy, Intensity-Modulated 53 Isotretinoin 53 Peripheral Blood Stem Cell Transplantation 52 Granulocyte Colony-Stimulating Factor 50 Erlotinib Hydrochloride 50 Everolimus 48 Chemotherapy, Adjuvant 48

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Dosage Forms × CNS × Clear all

NCT05309668 2025-12-18

SPRINKLE

AstraZeneca

Phase 1/2 Active not recruiting

36 enrolled 37 charts

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡